Breakthrough Science for Severe Viral Lung Infections

We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled IFN-β (SNG001) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs.

Need for more treatments

There remains an urgent clinical need for new therapies to treat those hospitalised with severe viral lung infections, including COVID-19, to prevent the progression to more severe disease and death.

Despite vaccination programmes and the availability of new early interventions, thousands of patients are being hospitalised with COVID-19 every day.


Photo courtesy of Cdc O Zc Q Ihid M Tw unsplash
Host-directed antivirals boost the cell’s immune responses, strengthening antiviral defences, so they are better able to fight off the virus.

Not all antivirals are the same

Watch this short animation to learn the difference between host-directed antivirals and direct acting antivirals.

The Need

The medical community recognises that there is no magic bullet to end the COVID-19 pandemic. It will require a full set of tools and treatments to meet the needs of different types of patients at different stages of the disease.

Viruses are wily creatures, and you’ve got to stay ahead of them. I think it would be naïve to think that if you get one or two good drugs, you don’t need any more — not when you have a virus that has already killed 760,000 Americans.

Dr. Anthony Fauci, The New York Times, 7 December 2021

The need for treatments for all stages of the disease is in fact more pronounced than ever. Never in the history of infectious-disease control have we been satisfied with just one set of tools.

Rachel Cohen, Director for Drugs for Neglected Disease Initiative, MIT Technology Review, 28 June 2021